Clinical Trial Update: Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial evaluates siltuximab to prevent severe immune-related adverse events during rechallenge with immune checkpoint inhibitors in patient…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies
• Solid Tumors

Drugs mentioned

• Siltuximab (siltuximab)

Snippet

Sponsor: Yuanquan Yang | Conditions: Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm | Phase 2 | Status: RECRUITING